Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457002 · ClinicalTrials.gov registry record · Phase 3
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,758
- Enrollment target
NCT00457002: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00457002 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 6,758 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (775% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00457002, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,758 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis \[DVT\]) and lung (pulmonary embolism \[PE\]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.
Primary Outcome
VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compre
Interventions
- DRUG Apixaban
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,758 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00457002 record still lists
NCT00457002 is an interventional study that assigns participants to a tested intervention. Its 6,758 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (775% higher).
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT00457002 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00457002 about?
NCT00457002 is a clinical study titled "Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness". The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis \[DVT\]) and lung (pulmonary embolism \[PE\]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preven...
What is the current status of trial NCT00457002?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,758 participants. The study started on 2007-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00457002?
The interventions under investigation include: Apixaban (DRUG), Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00457002?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00457002's enrollment target sits among peer trials
6,758 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03887715 · 6,800 participants · NA
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- NCT05121324 · 6,700 participants · Phase 3
Pediatric Dose Optimization for Seizures in Emergency Medical Services
- NCT06234384 · 6,833 participants
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia